Oxford Immunotec Global (Oxford Immunotec Global) Capital Expenditure : $-4.90 Mil (TTM As of Sep. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Oxford Immunotec Global Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Oxford Immunotec Global's cash flow for capital expenditures for the three months ended in Sep. 2020 was $-1.56 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2020 was $-4.90 Mil.

Oxford Immunotec Global Capital Expenditure Historical Data

The historical data trend for Oxford Immunotec Global's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Immunotec Global Capital Expenditure Chart

Oxford Immunotec Global Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Capital Expenditure

Get a 7-Day Free Trial

-3.47

-0.86

-1.30

-5.35

-1.66

Oxford Immunotec Global Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Capital Expenditure	Get a 7-Day Free Trial															-0.21	-0.93	-0.61	-1.81	-1.56

Oxford Immunotec Global Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.90 Mil.

Oxford Immunotec Global (Oxford Immunotec Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Oxford Immunotec Global PLC (NAS:OXFD) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

143 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4SE

Website

http://www.oxfordimmunotec.com

Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.

Executives

Andrew Scott Walton	director	430 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark R. Klausner	director	C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Patricia Randall	director	C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Richard A Sandberg	director	330 NEVEDA STREET, NEWTON MA 02460-1458
Patrick J Balthrop	director	C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Herm Rosenman	director	OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008
Peter Wrighton-smith	director, officer: Chief Executive Officer	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Mclaughlin Matthew T E	officer: Chief Financial Officer	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Stefan C Linn	officer: Chief Operating Officer	C/O OXFORD IMMUNOTEC GLOBAL 940 INNOVATION DRIVE MILTON PARK ABINGDON X0 OX14 4RZ
Janet Louise Kidd	officer: General Counsel	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Elizabeth M Keiley	officer: SVP & General Counsel	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Richard M. Altieri	officer: Chief Financial Officer	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Richard Wenstrup	officer: Chief Medical Officer	C/O OXFORD IMMUNOTEC GLOBAL, 94C INNOVATION DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RZ